Polpharma Biologics works with partners to advance their biological pipeline (biosimilars and novel biologics) by providing world-class contract development and manufacturing services to the industry to help partners take their product from concept to commercial supply.

For the development of novel biologics, they also provide proprietary solutions for discovery (CASH™), cell line development (CHO^BC®), and process development (SPOT™ and SLIM™) to achieve high yields and high quality and to accelerate products to patients.

For biosimilars, their capabilities are designed to help partners provide patients worldwide with access to the most advanced life-saving and life-improving therapies available. They leverage their large molecule capabilities to develop biosimilars that have no meaningful difference from their reference product in terms of safety and efficacy and are more affordable than the originator drug.

Polpharma Biologics is also expanding its drug substance manufacturing capacity with a large-scale manufacturing plant in Warsaw to increase its ability to assist partners with their clinical and commercial supply.